BioSpace News Archive

Motus GI Holdings, Inc. reported its financial results for the quarter ended March 31, 2019 and provided a corporate update.

NeuroVive Pharmaceutical AB announced that the US Food and Drug Administration, FDA, has approved NeuroVive’s IND (Investigational New Drug) application, enabling clinical studies in the US with the company’s drug candidate NeuroSTAT in development for treatment of moderate to severe traumatic brain injury, TBI.

The 2019 Stephen Hawking Medal for science communication comes a year after the great scientist’s passing

Sobi™ and Sanofi will present data demonstrating that Elocta® and Alprolix® can provide perioperative haemostatic control across a wide spectrum of major and minor surgeries in subjects of all ages with severe haemophilia A and B respectively.

During the Honorary Gala celebrating the Right Honourable Brian Mulroney, the Fondation du Centre hospitalier de l’Université de Montréal raised over $3.6 million, one of the largest amounts ever raised in Canada for this type of event.

Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM)

Owens & Minor, Inc. (NYSE: OMI) today announced that its Board of Directors has approved a second quarter dividend payment of $0.0025 per share.

Cipher Pharmaceuticals Inc. (TSX:CPH) (“Cipher” or “the Company”) today announced its financial and operating results for the three months ended March 31st, 2019.

Neptune Wellness Solutions Inc. (“Neptune” or the “Corporation”) (NASDAQ: NEPT) (TSX: NEPT), announced that it has settled regarding certain claims made by the Corporation’s former chief executive officer (the “Former CEO”) against the Corporation in respect of the termination of his employment with the Corporation.

Investigators from around the country presented hundreds of studies about kidney health and chronic kidney disease during the National Kidney Foundation’s 2019 Spring Clinical Meetings in Boston, May 8-12.